Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.24%11.96B | 1.38%3.09B | -0.62%2.9B | 3.14%3.15B | -3.13%2.82B | 0.58%11.93B | 2.94%3.05B | -4.76%2.92B | 3.00%3.06B | 1.36%2.91B |
Net interest income | -2.43%7.44B | -5.51%1.89B | -1.64%1.85B | -2.06%1.85B | -0.27%1.85B | 0.91%7.63B | 3.05%2B | -0.84%1.89B | 1.23%1.89B | 0.16%1.86B |
-Total interest income | -2.37%7.54B | -5.40%1.91B | -1.57%1.88B | -2.04%1.88B | -0.27%1.88B | 0.85%7.73B | 3.11%2.02B | -0.83%1.91B | 1.22%1.92B | -0.16%1.88B |
-Total interest expense | 2.04%100M | 4.00%26M | 4.00%26M | 0.00%25M | 0.00%23M | -3.92%98M | 8.70%25M | 0.00%25M | 0.00%25M | -20.69%23M |
Non interest income | 4.97%4.52B | 14.48%1.2B | 1.25%1.05B | 11.57%1.3B | -8.17%966M | 0.00%4.31B | 2.74%1.05B | -11.15%1.04B | 5.99%1.17B | 3.54%1.05B |
-Fees and commissions | 17.78%1.62B | 31.51%505M | 24.92%386M | 22.56%478M | -13.90%254M | -14.83%1.38B | 0.79%384M | -32.24%309M | -5.57%390M | -19.84%295M |
-Including:Fees and commission income | 8.68%2.79B | 20.54%798M | 2.46%624M | 14.49%798M | -4.83%572M | -5.79%2.57B | -2.65%662M | -7.31%609M | -3.73%697M | -9.76%601M |
-Including:Fees and commission expense | -1.85%1.17B | 5.40%293M | -20.67%238M | 4.23%320M | 3.92%318M | 7.39%1.19B | -7.02%278M | 49.25%300M | -1.29%307M | 2.68%306M |
-Total other operating income | -1.06%2.9B | 4.65%697M | -8.80%663M | 6.05%824M | -5.94%712M | 8.93%2.93B | 3.90%666M | 2.39%727M | 12.94%777M | 16.82%757M |
Credit losses provision | 2.62%274M | -67.83%267M | ||||||||
Operating expense | -0.23%10.5B | 0.26%2.31B | 0.69%2.78B | 1.23%2.8B | -3.09%2.6B | 2.73%10.52B | 13.38%2.31B | -1.39%2.76B | 0.91%2.77B | 0.83%2.69B |
Selling and administrative expenses | 0.73%7.84B | 1.69%1.98B | -2.73%1.96B | 2.31%1.95B | 1.83%1.95B | 1.25%7.79B | 2.20%1.95B | 4.62%2.02B | 0.69%1.91B | -2.45%1.91B |
-General and administrative expense | 0.73%7.84B | 1.69%1.98B | -2.73%1.96B | 2.31%1.95B | 1.83%1.95B | 1.25%7.79B | 2.20%1.95B | 4.62%2.02B | 0.69%1.91B | -2.45%1.91B |
Other operating expenses | -2.96%2.65B | -7.56%330M | 9.96%817M | -1.16%849M | -15.23%657M | 7.22%2.73B | 181.10%357M | -14.70%743M | 1.42%859M | 9.93%775M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -5M | -1M | -2M | -2M | 0 | 0 | 0 | 0 | 0 | 0 |
Less:Other special charges | --5M | --1M | --2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Income before tax | 3.50%1.18B | 5.72%499M | -24.69%122M | 20.76%349M | -3.17%214M | 48.38%1.14B | 790.57%472M | -39.33%162M | 27.31%289M | -1.34%221M |
Income tax | 19.32%315M | 0 | 146.67%74M | 91.58%182M | 742.86%59M | 532.79%264M | 154.10%132M | -57.75%30M | 82.69%95M | -88.33%7M |
Net income | -1.14%869M | 47.20%499M | -63.16%49M | -13.47%167M | -28.04%154M | 5.52%879M | 13.38%339M | -31.79%133M | 10.29%193M | 30.49%214M |
Net income continuous operations | -1.25%869M | 46.76%499M | -63.64%48M | -13.92%167M | -27.57%155M | 5.77%880M | 14.48%340M | -32.65%132M | 10.86%194M | 30.49%214M |
Noncontrolling interests | -70.00%3M | -50.00%1M | -33.33%2M | -400.00%-3M | -25.00%3M | 66.67%10M | 2M | 0.00%3M | -66.67%1M | 4M |
Net income attributable to the company | -0.23%866M | 48.07%499M | -64.34%46M | -10.94%171M | -28.57%150M | 5.08%868M | 13.09%337M | -33.16%129M | 11.63%192M | 28.83%210M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | ||||||||||
Net income attributable to common stockholders | -0.23%866M | 48.07%499M | -64.34%46M | -10.94%171M | -28.57%150M | 5.08%868M | 13.09%337M | -33.16%129M | 11.63%192M | 28.83%210M |
Gross dividend payment | ||||||||||
Basic earnings per share | -0.23%30.98 | 48.26%17.85 | -64.72%1.63 | -11.05%6.12 | -28.36%5.38 | 5.04%31.05 | 12.73%12.04 | -32.85%4.62 | 11.69%6.88 | 28.60%7.51 |
Diluted earnings per share | -0.23%30.98 | 48.16%17.8382 | -64.65%1.63 | -10.93%6.1133 | -28.36%5.38 | 5.04%31.05 | 13.03%12.04 | -32.98%4.6113 | 11.63%6.8633 | 28.60%7.51 |
Dividend per share | 0.00%5 | 0.00%5 | 0 | 0 | 0 | 0.00%5 | 0.00%5 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |